Asian Journal of Cardiology Research

Background: Curbing the prevalence rates of ischemia heart disease presents a formidable challenge owing to a complex interplay of determinants such as low diagnostic rates, poor patient medication adherence, and less practice of evidence-based interventions. Ischemia Reversal Program (IRP) is an alternative therapy for ischemic heart disease patients, it is a combination of Panchakarma and allied therapy. The study intended to assess the role of IRP in improving quality of life by reducing myocardial ischemia and risk of heart disease.

Methods: A prospective, observational, single-centre study was conducted at Madhavbaug Cardiac Care Clinic from March 2021 to December 2022. Patients aged 18 years and above diagnosed with ischemic heart disease and that had participated in the IRP for a minimum of 7 sessions over a 90-day duration were included in this study. Data at baseline was compared with data at the 90-day follow-up.

Results: Of the 35 patients screened, 23 patients were included in the present study. Mean age of the study patients was 55.30 ± 8.01 years and 78.3% were male. The VO₂ peak significantly improved from 17.53 ± 9.17 on day 1 to 26.93 ± 7.71 at day 90.

Conclusion: The IRP can be an effective treatment to reduce risk of mortality due to heart disease and to improve quality of life in stable ischemic heart disease patients.